TTC Safety in HER2+ Metastatic Breast Cancer: Key Findings
A detailed safety assessment of the combination of tucatinib with trastuzumab and capecitabine (TTC) was published in The Oncologist.
Useful takeaways from this story.
A detailed safety assessment of the combination of tucatinib with trastuzumab and capecitabine (TTC) was published in The Oncologist.
Jessica Nye, Ph From: oncologynurseadvisor.com n a safety review of the HER2CLIMB trial, grade 3 or higher AEs occurred in 55.2% of patients receiving TTC compared with 48.7% receiving placebo, with...
By: Jessica Nye, Ph From: oncologynurseadvisor.com n a safety review of the HER2CLIMB trial, grade 3 or higher AEs occurred in 55.2% of patients receiving TTC compared with 48.7% receiving placebo, with...
Building the complete brief
The page is ready to read now. The fuller skim-friendly version will appear here automatically.
The useful part
A detailed safety assessment of the combination of tucatinib with trastuzumab and capecitabine (TTC) was published in The Oncologist. Jessica Nye, Ph From: oncologynurseadvisor.com n a safety review of the HER2CLIMB trial, grade 3 or higher AEs occurred in 55.2% of patients receiving TTC compared with 48.7% receiving placebo, with diarrhea being the primary AE requiring dose modifications. The post TTC Safety in HER2+ Metastatic Breast Cancer:
Details worth keeping
Jessica Nye, Ph From: oncologynurseadvisor.com n a safety review of the HER2CLIMB trial, grade 3 or higher AEs occurred in 55.2% of patients receiving TTC compared with 48.7% receiving placebo, with diarrhea being the primary AE requiring dose modifications. The post TTC Safety in HER2+ Metastatic Breast Cancer:
Keep reading in the app
Open the app view to save this story, compare related coverage, and continue from the same source.